Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function

Drugs in R and D

Volumn 8, Issue 3, 2007, Pages 145-153

  Saraceni, Christine ^a   Broderick, Tom L ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIM 51077; CJC 1134; CJC 1134PC; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; EXENDIN (9-39); EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; HYPERTENSIVE AGENT; LIRAGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADJUVANT THERAPY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; CHRONOTROPISM; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG POTENCY; HEART FAILURE; HEART PERFORMANCE; HEART PROTECTION; HEMODYNAMICS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INOTROPISM; INSULIN LIKE ACTIVITY; MONOTHERAPY; NAUSEA AND VOMITING; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SOLITARY TRACT NUCLEUS; STOMACH DISCOMFORT;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BRAIN; CARDIOVASCULAR PHYSIOLOGY; DIABETES MELLITUS; DYSLIPIDEMIAS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIUM; RECEPTORS, GLUCAGON;

EID: 34248191802     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708030-00002     Document Type: Review

References (41)

1. Brubaker PL. Glucagon-like peptide-1: a novel therapeutic agent for the treatment of type 2 diabetes. Can J Diab Care 1999; 23: 39-46
2. Drucker DJ. Glucagon-like peptides. Diabetes 1997; 47: 159-69
3. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertension 2003; 21: 1125-35
4. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52
5. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type 1 diabetic patients. Diabetes Care 1996; 19: 580-6
6. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 316-22
7. D'Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide 1. Diabetes 1995; 44: 1433-7
8. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20
9. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81: 327-32
10. Juntti-Berggren L, Pigon J, Karpe F, et al. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care. 1996; 19: 1200-6
11. De Leon DD, Crutchlow MF, Ham JYN, et al. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006; 38: 845-59
12. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4. Diabetes 1999; 48: 1026-34
13. Luque MA, Gonzalez N, Marquez L, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 2002; 173: 465-73
14. Vila Petroff MGV, Egan JM, Wang X, et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001; 89: 445-52
15. Egan JM, Montrose-Rafizadeh C. Wang Y, et al. Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3t3-l1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 1994; 135: 2070-5
16. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-51
17. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242-52
18. Baggio LL, Drucker DJ. American Diabetes Association 66th Scientific Sessions. Incretin analogs other than Exenatide [online]. Available from URL: http://www.medscape.com/viewarticle/540919/ [Accessed 2006 Nov 21]
19. Cornell S. LAF 237: a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. J Pharm Technol 2006; 22: 1-5
20. Hui H, Farilla L, Merkel P, et al. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002; 146: 863-9
21. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol 2005; 289: H2401-8
22. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110: 894-6
23. Barragan JM, Rodriguez RE, Eng J, et al. Interactions of exendin-(9-39) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996; 67: 63-8
24. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 2004; 287: E1209-15
25. Buyukcoskun NI, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 2004; 118: 33-8
26. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266: E459-66
27. Gardiner SM, March JE, Kemp PA, et al. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006; 316: 852-9
28. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-61
29. Barragan JM, Eng J, Rodriguez R, et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999; 277: E784-91
30. Edwards CMB, Edwards AV, Bloom SR. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf. Exp Physiol 1997; 82: 709-16
31. Zhao T, Parkkh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106-13
32. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-24
33. Nystrom T, Gonon AT, Sjoholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173-7
34. Kavianipour M, Ehlers MR, Malmberg K, et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003; 24: 569-78
35. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1999, 1143
36. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions; 2006 June 9-13; Washington (DC). Diabetes 2006; 55 Suppl. 1: 2007-PO
37. Thrainsdottir I, Malmberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Res 2004; 1: 40-3
38. Kapitza C, Heise T, Klein O, et al. BIM51077, a novel GLP-1 analog, achieves sustained improvement in blood glucose control over 28 days of treatment. In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions; 2006 June 9-13; Washington (DC). Diabetes 2006; 55 Suppl. 1: 500-P
39. Thibaudeau K, Robitaille M, Wen S, et al. CJC-1134-PC: An exendin-4 conjugate with extended pharmacodynamic profiles in rodents. In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions; 2006 June 9-13; Washington (DC). Diabetes 2006; 55 Suppl. 1: 434-P
40. Baggio LL, Huang Q, Drucker DJ. The long-acting albumin-exendin-4 GLP-1R agonist CJC-1134 engages central and peripheral mechanisms regulating glucose homeostasis. In: Program and abstracts of the American Diabetes Association 66th Scientific Sessions; 2006 June 9-13; Washington (DC). Diabetes 2006; 55 Suppl. 1: 362-OR
41. Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regulatory Peptides 2001; 102: 81-6